JAZZ News and Press, Jazz Pharmaceuticals plc From 03/24/22

Jazz Pharmaceuticals (NASDAQ:JAZZ) said the first patient was enrolled in a phase 2 trial evaluating Zepzelca (lurbinectedin) as a monotherapy in three groups: patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination deficient (...

Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca® (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors PR Newswire Open-label basket trial will assess the safety and eff...

We are initiating AVDL at a speculative buy rating, with a target price of USD 14. We like AVDL's lead candidate FT218, and we believe the upcoming PDUFA on March 31st to be the critical catalyst for the company. We believe AVDL will be able to generate USD ~300M peak sales. ...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with this event. For further details see: Jazz Pharmaceuticals (JAZZ) Presents at the Needham Virtual Neuroscience Forum - Slideshow

Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting PR Newswire DUBLIN , March 8, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that pre-clinical...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Shares of the mid-cap biotech Jazz Pharmaceuticals (NASDAQ: JAZZ) were up by 12.2% as of 1:19 p.m. ET on Wednesday. The drugmaker's stock is up today in response to its better-than-expected 2021 fourth-quarter and full-year results. What's the main impetus behind today's dou...

Jazz Pharmaceuticals (JAZZ +12.1%) has recorded the biggest intraday gain since 2017 on Wednesday to reach a six-month high on the strong Q4 earnings beat reported by the Neuroscience-focused biopharmaceutical company yesterday. Jazz (NASDAQ:JAZZ) reported more than $3B annual revenue for the...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2021 Q4 earnings call. For further details see: Jazz Pharmaceuticals plc 2021 Q4 - Results - Earnings Call Presentation

Jazz Pharmaceuticals plc (JAZZ) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Co-Founder, Chairman & CEO Daniel Swisher - President Robert Iannone - EVP, Research & Development & Chief Medical Officer...